SCHEMBL27002115

SCHEMBL27002115

CC/C(=C\c1cc(OC)c(Br)cc1OC)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.42
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
TNFRSF1A P19438 1/20 0.40
MAPT P10636 1/20 0.40
HTR2A P28223 3/20 0.39
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
KDM1A O60341 1/20 0.37
NFE2L2 Q16236 1/20 0.37
PPARG P37231 1/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 1/20 0.36
SLC16A3 O15427 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29279528 1.00 PRKDC (0.42) PRKDCLCKFYNTNFRSF1AMAPT
SCHEMBL29279594 0.85 LMNA (0.44) PRKDCMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL27368417 0.85 LMNA (0.44) PRKDCMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL27002162 0.81 PRKDC (0.47) PRKDCLCKFYNTNFRSF1AMAPT
SCHEMBL3327239 0.81 MAPT (0.51) TNFRSF1AMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL3327232 0.81 MAPT (0.51) TNFRSF1AMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL2389154 0.78 PSEN1 (0.51) MAPTALDH1A1HPGDPSEN1PSEN2
SCHEMBL2690714 0.77 PPARG (0.50) MAPTPPARGPSEN1PSEN2APH1B
SCHEMBL27188081 0.75 PRKDC (0.41) PRKDCTNFRSF1AMAPTHTR2AALDH1A1
SCHEMBL27188085 0.75 PRKDC (0.41) PRKDCTNFRSF1AMAPTHTR2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166618-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME GILGAMESH PHARMACEUTICALS, INC. (US) 2024-05-23 US disclosed
CN-117642379-A Phenylalkylamines and methods of making and using the same 吉尔伽美什制药公司 2024-03-01 CN disclosed
EP-4305019-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME Gilgamesh Pharmaceuticals, Inc. (US) 2024-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166618-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME PNMT, HTR6, HTR2C PRKDC 1024/4885LCK 2285/4885FYN 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.